Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurine Treatment for Multiple Sclerosis
NCT07263607Phase 2Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of taurine in multiple sclerosis (MS) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: MRI lesion activity at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
taurine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07263607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263607.